These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32365349)

  • 1. Health-Related Quality of Life in Patients with Multiple Endocrine Neoplasia Type 1.
    van Leeuwaarde RS; Pieterman CRC; May AM; Dekkers OM; van der Horst-Schrivers AN; Hermus AR; de Herder WW; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
    Neuroendocrinology; 2021; 111(3):288-296. PubMed ID: 32365349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Fear of Disease Occurrence Is Associated With Low Quality of Life in Patients With Multiple Endocrine Neoplasia Type 1: Results From the Dutch MEN1 Study Group.
    van Leeuwaarde RS; Pieterman CRC; Bleiker EMA; Dekkers OM; van der Horst-Schrivers AN; Hermus AR; de Herder WW; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2354-2361. PubMed ID: 29618015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors.
    de Laat JM; Tham E; Pieterman CR; Vriens MR; Dorresteijn JA; Bots ML; Nordenskjöld M; van der Luijt RB; Valk GD
    Eur J Endocrinol; 2012 Aug; 167(2):181-7. PubMed ID: 22581216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clues For Genetic Anticipation In Multiple Endocrine Neoplasia Type 1.
    van den Broek MFM; van Nesselrooij BPM; Pieterman CRC; Verrijn Stuart AA; van de Ven AC; de Herder WW; Dekkers OM; Drent ML; Havekes B; Kerstens MN; Bisschop PH; Valk GD
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32396602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1).
    Berglund G; Lidén A; Hansson MG; Oberg K; Sjöden PO; Nordin K
    Fam Cancer; 2003; 2(1):27-33. PubMed ID: 14574164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs.
    van Vliembergen ENM; Eijkelenkamp H; Valk GD; Vriens MR; Meijer GJ; Intven MPW; de Laat JM
    Front Endocrinol (Lausanne); 2023; 14():994370. PubMed ID: 37305036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial burden is associated with worse health-related quality of life in adults with multiple endocrine neoplasia type 1.
    Peipert BJ; Goswami S; Helenowski I; Yount SE; Sturgeon C
    Surgery; 2017 Dec; 162(6):1278-1285. PubMed ID: 28923697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Care for patients with multiple endocrine neoplasia type 1: the current evidence base.
    Pieterman CR; Vriens MR; Dreijerink KM; van der Luijt RB; Valk GD
    Fam Cancer; 2011 Mar; 10(1):157-71. PubMed ID: 21061174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
    Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
    Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of genotype-phenotype correlations and survival outcomes in patients with primary hyperparathyroidism caused by multiple endocrine neoplasia type 1: the experience at a single institution.
    Horiuchi K; Okamoto T; Iihara M; Tsukada T
    Surg Today; 2013 Aug; 43(8):894-9. PubMed ID: 23052745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.
    Nell S; Borel Rinkes IHM; Verkooijen HM; Bonsing BA; van Eijck CH; van Goor H; de Kleine RHJ; Kazemier G; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; Vriens MR;
    Ann Surg; 2018 Feb; 267(2):352-356. PubMed ID: 27811505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group.
    van Leeuwaarde RS; van Nesselrooij BP; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; de Laat JM; Pieterman CR; Valk GD
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1159-65. PubMed ID: 26751192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease and treatment factors associated with lower quality of life scores in adults with multiple endocrine neoplasia type I.
    Goswami S; Peipert BJ; Helenowski I; Yount SE; Sturgeon C
    Surgery; 2017 Dec; 162(6):1270-1277. PubMed ID: 28919050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.
    Marini F; Giusti F; Brandi ML
    Orphanet J Rare Dis; 2018 Nov; 13(1):205. PubMed ID: 30428914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.
    Pieterman CRC; de Laat JM; Twisk JWR; van Leeuwaarde RS; de Herder WW; Dreijerink KMA; Hermus ARMM; Dekkers OM; van der Horst-Schrivers ANA; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3795-3805. PubMed ID: 28938468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEN1-Dependent Breast Cancer: Indication for Early Screening? Results From the Dutch MEN1 Study Group.
    van Leeuwaarde RS; Dreijerink KM; Ausems MG; Beijers HJ; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Peeters PHM; Pijnappel RM; Vriens MR; Valk GD
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2083-2090. PubMed ID: 28323962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
    Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
    Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple endocrine neoplasia type 1 in Poland: a two-centre experience.
    Soczomski P; Jurecka-Lubieniecka B; Rogozik N; Tukiendorf A; Jarząb B; Bednarczuk T
    Endokrynol Pol; 2019; 70(5):385-391. PubMed ID: 31274185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
    Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
    Sadowski SM; Pieterman CRC; Perrier ND; Triponez F; Valk GD
    Endocr Relat Cancer; 2020 Jun; 27(6):R145-R161. PubMed ID: 32229700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.